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SUMMARY: MR imaging is widely used for the diagnosis and monitoring of patients with MS.
Applications and protocols for MR imaging continue to evolve, prompting a need for continual
reassessments of the optimal use of this technique in clinical practice. This article provides updated
recommendations on the use of MR imaging in MS, based on a review of the trial evidence and
personal experiences shared at a recent expert meeting of radiologists and neurologists.
ABBREVIATIONS: BBB  blood-brain barrier; CIS  clinically isolated syndrome; CNS  central
nervous system; DTI  diffusion tensor imaging; DWI  diffusion-weighting imaging; FLAIR 
fluid-attenuated inversion recovery; Gd  gadolinium; IFNB  interferon ; MS  multiple sclero-
sis; NSF  nephrogenic systemic fibrosis
MR imaging has played an increasing role in the diagnosisandmanagement ofMS.1 It offers 3main applications in
MS. First, in combination with characteristic symptoms, it
provides earlier andmore confident diagnosis than symptoms
alone.2 Second, it contributes to our understanding of the
pathophysiology of MS and how pathophysiologic changes
relate to clinical manifestations of disease.3 Third, it has a role
in monitoring the effects of therapies in clinical trials and also
has the potential to identify response to therapy in individual
patients.4,5
Contrast agents are conventionally included in acquisition
protocols for MR imaging. Use of these agents also offers in-
sights into pathogenesis and enhances themonitoring of treat-
ment effects.6
As applications for MR imaging in MS evolve and increas-
ing numbers of techniques and protocols are adopted, there is
a trend toward variation in the use of MR imaging among
centers. In the face of this growing divergence, experts recog-
nize the importance of standardizing protocols based on evi-
dence of optimal practice.6 This review seeks to contribute to
this important objective by reporting an expert meeting that
focused on discussions and recommendations for the optimal
use of MR imaging in MS by neurologists and radiologists—
key participants in the use of contrast-enhanced MR imaging
in MS.
Applications of MR Imaging in MS
MR imaging offers clinicians a range of applications for the
management of MS, including support in diagnosis, insights
into pathogenesis, an understanding of prognosis relevant to
individual patients, and assistance inmonitoring the effects of
therapy.
Support in Diagnosis
A diagnosis of MS is founded on clinical evaluation. Several
criteria have been developed to integrate MR imaging with
clinical evaluation and other diagnostic methods to achieve
earlier andmore accurate diagnosis, including the revisedMc-
Donald criteria.2
The McDonald criteria were the first to incorporate the
brain and spinal cord lesions visualized on MR imaging into
traditional diagnostic approaches, including history, exami-
nation, and laboratory tests.7 The revised McDonald criteria
included amendments to the original guidelines to facilitate
use in typical practice settings.2 Specifically, these revisions
were designed to help demonstrate lesion dissemination in
time, clarify the evaluation of spinal cord lesions, and simplify
the diagnosis of primary-progressive disease.
The revisedMcDonald criteria have largely superseded ear-
lier criteria7-9 and represent an important element in the diag-
nosis of patients with suspected MS. The revised McDonald
criteria have, however, been criticized for their perceived com-
plexity and low (60%) sensitivity.10
Less complex criteria have been produced, such as the Swan-
ton criteria, which are claimed to offer similar specificity (87%)
but increased sensitivity (72%) compared with the McDonald
criteria.10 Despite apparent advantages for the Swanton criteria,
there has been hesitation amongmost clinicians to adopt them.
Another study investigating simplified criteria for diagnosing
MS reported that a single MR imaging study performed 3
months after the onset of CIS is highly specific for the develop-
ment of clinically definiteMS in the presence of dissemination in
space, providing that both gadolinium-enhancing and -nonen-
hancing lesions are found, indicative of dissemination in time.11
These interesting results require confirmation.
Consensus Statement.MR imaging has an important role
in the diagnosis of MS. Expert meeting participants recom-
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mended adopting standardized protocols and reporting pro-
cedures based on the revised McDonald criteria.
Regional Differences in Characteristics of MS Lesions
The presentation of MS typically differs between Asian and
Western populations.12 In Asian patients, the optic-spinal
type ofMS is more frequent, an older age group (35 years) is
affected, fewer cases are positive for oligoclonal bands, and
total protein concentrations in CSF are higher. When spinal
involvement occurs, the lesion is characteristically longer.
Caution should be exercised when applying the McDonald
criteria in Asian patients because of the characteristic differ-
ences in lesion location compared with Western patients. In-
clusion of a spinal cord lesion as a juxtacortical lesion increases
sensitivity for diagnosis.13 The criteria of Poser et al9 are con-
sidered more reliable than the McDonald criteria in Asian
populations, though they are not dependable for early
diagnosis.
Consensus Statement. MR imaging evaluation in Asian
populations should focus on the optic nerve and spinal cord.
Given the frequency of spinal cord involvement in Asian pa-
tients with MS, McDonald criteria require modification for
these patients.
Insights into Pathogenesis
MS is a complex immune disease in which self-reactive T-cells
and monocytes mediate inflammation of CNS white matter
and demyelination of axons, leading typically to cumulative
neurologic disability.14 MR imaging provides insights into the
pathogenic processes ofMS, alongside other noninvasive tech-
niques and clinical evaluation. In particular, MR imaging by
using gadolinium-containing contrast agents has helped iden-
tify the pivotal role of the BBB.15 Breaching the BBB by im-
mune cells mediates structural and functional changes in the
CNS of patients with MS, including inflammation, demyeli-
nation, axonal loss, remyelination, and gliosis. Demonstrating
BBB disruption at MR imaging may represent one of the ear-
liest indications for a diagnosis of MS. Insights into pathogen-
esis provided by MR imaging have also offered greater under-
standing of the mechanisms of action of first-line drugs,
IFNB,16 and glatiramer acetate.17
Understanding the Prognosis
An important objective in management is predicting the dis-
ease course in individual patients. For patients with CIS, the
objective is to predict conversion to clinically definite MS. In
patients with CIS suggestive of an MS attack and lesions on
MR imaging, the likelihood of developing clinically definite
MS is 88% during 14 years18 and 82% during 20 years.19 In
established disease, objectives in management are to predict
relapse in the short-term and predict disability and sustained
disease progression in the long-term. A relapsing course is
followed by sustained progression within 2 decades in 80% of
cases.20
Disease progression is highly variable between individuals,
reflecting the complex nature of the disease and variations in
capacity for repair and compensation.21 Conventional MR
imaging measures, including T2 lesion load, correlate poorly
with clinical outcomes in MS,19,22 and correlations tend to
weaken further in later stages of disease.23Meta-analysis of the
predictive value of gadolinium-enhanced MR imaging simi-
larly indicates a low ability to predict relapses and develop-
ment of impairment and disability (Fig 1).24
A number of explanations have been suggested for whyMR
imaging assessments are dissociated from clinical status and
the development of disability—the so-called “clinicoradio-
logic paradox”:
● Deficiencies in clinical and MR imaging assessments.
● The presence of strategic-versus-nonstrategic lesions.
● The dual role of the immune system, both in destroying and
promoting repair.
● The role of neurodegenerative processes that gain impor-
tance as the disease progresses.
● Abnormalities of apparently normal white and gray matter.
● The role of adaptation and reorganization in compensating
disease-related damage.
Consensus Statement.More reliable and standardized ap-
proaches toMR imaging assessments inMSmay lead to better
correlationwith clinical course.Until the reasons that underlie
the clinicoradiologic paradox are fully identified, prognosis in
individual patients cannot be based on MR imaging findings
alone.
Monitoring Therapy
MR imaging is widely used to investigate the anti-inflamma-
tory effects of therapies in clinical trials. In this setting, the
most widely adopted and best-supported MR imaging assess-
ments are T2 (for lesion load and new and enlarging lesions)
and gadolinium-enhanced T1 (for total lesion number, new
and enlarging lesions, and lesion load).
The Prevention of Relapses and Disability by Interferon-
Beta1a Subcutaneously inMultiple Sclerosis trial includedMR
imaging assessments in patients with clinically definite or lab-
oratory-supported relapsing-remitting MS. T2 and gadolini-
um-enhanced T1MR imaging identified the onset ofmaximal
therapeutic effect for IFNB-1a at 3 months.4 Other investiga-
tions, such as the fingolimod phase II study, similarly demon-
strated the utility of MR imaging to monitor the effects of
therapy in a trial setting.25 In confirmation of individual stud-
ies, a recent meta-analysis reported strong correlations be-
tween the effects of therapies on relapses and their influence
on MR imaging activity.26
Fig 1. Predictive value of gadolinium-enhanced MR imaging for relapses in MS: a
meta-analysis. Reprinted with permission from Lancet.24
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Less convincing evidence is available to support a role for
other MR imaging measures in monitoring the effects of ther-
apy, including T1 “black holes” (hypointense lesions) or atro-
phy of the brain or cord, and even less evidence supports a role
formagnetization transferMR imaging, DTI, spectroscopy, or
functional MR imaging—though these remain areas of active
investigation.27
Some centers routinely use MR imaging to monitor re-
sponse to therapy in individual patients. If neurologists choose
to useMR imaging tomonitor a patient’s response to therapy,
a rational approach is baseline assessment with follow-up at 3
or 6 months and again at 12 months. Reassessment with MR
imaging may be sooner if there are concerns about the pa-
tient’s disease course. Stable MR imaging assessments in an
individual with clinically silent disease supports continuation
of the current treatment. Identification of new lesions in a
clinically silent individual may indicate a change in therapy or
the need for more frequent follow-up. A major increase in
lesion number in a modestly clinically active patient or a pa-
tient with indeterminate findings indicates that therapy
should be re-evaluated.
Consensus Statement. MR imaging has utility for moni-
toring the effects of therapies in clinical trials. Further evi-
dence is needed to support a role for MR imaging in monitor-
ing therapeutic response in routine clinical practice.
Benefits of Early Therapy in MS
There is an encouraging trend toward initiating therapy early
in the disease course, so now almost all patients with MS are
treated following the first event. The rationale for early initia-
tion of therapy is to reduce the frequency of relapses and slow
progression to disability.
Outcomes from well-designed placebo-controlled trials of
IFNB indicate that early treatment—at the first clinical demy-
elinating event—can slow progression to clinically definite
MS.5,28-31 Serial MR imaging assessments, including T2 and
gadolinium-enhanced T1 scans, supported clinical observa-
tions of improvement in these trials.
Most trials investigating the benefits of early treatment
have been short-term. An exception is a large observational
study of early treatment with IFNB in 1504 patients with re-
lapsing-remitting MS who were followed for 7 years.32 Pa-
tients treated with IFNB showed significant reductions in sec-
ondary progression compared with a placebo, and the authors
concluded that early treatment slowed long-term progression
of MS.
Consensus Statement. Early initiation of treatment offers
benefits in most patients, and these benefits appear to persist
for the long-term. MR imaging contributes to the early initia-
tion of treatment by facilitating early diagnosis.
Techniques and Protocols for MR Imaging in MS
Conventional MR imaging
ConventionalMR imaging is a reliable and accurate diagnostic
technique, providing positive findings in approximately 95%
of patients with clinically definite MS. MR imaging is widely
recognized as superior to other imaging modalities, including
CT, for the visualization of lesions, particularly smaller le-
sions, and has largely replaced alternative imaging techniques
in practice.
MS plaques can be characterized at MR imaging by their
location, morphology, signal intensity, and degree of gadolin-
ium enhancement. Acute-phase plaques appear as rounded
areas of high-signal intensity on T2 sequences. Gadolinium
enhancement on T1 sequences is related to BBB damage asso-
ciated with inflammation. There are 2 patterns of enhance-
ment: uniform enhancement, reflecting the onset of a new
lesion, and ringlike enhancement, indicating reactivation of
an older lesion.33 Nonenhancing lesions are the result of ear-
lier episodes of disease. T2-weighted MR imaging is consid-
ered the most sensitive diagnostic test for demonstrating dis-
ease dissemination, but with moderate specificity. T1-
weighted gadolinium-enhanced imaging offers increased
specificity by differentiating enhancing from nonenhancing
lesions. Use of both of these imaging techniques provides op-
timal specificity.34
Typical MR imaging findings that are sensitive and specific
for diagnosing MS include plaques along callososeptal inter-
faces and perivenular extension (Dawson finger) (Fig 2).35
Fig 2. Typical MS with brain lesions.
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Atypical MR imaging findings in MS include lesions that
mimic tumors and autoimmune vasculitis. In these cases,
characteristic differences in lesion distribution, supported by
clinical and laboratory investigations, assist differential diag-
nosis. The revised McDonald criteria include recommenda-
tions for excluding alternative diagnoses through history, clin-
ical evaluation, and appropriate laboratory studies,2 while
“red flags” have been developed to alert clinicians to recon-
sider the differential diagnosis more extensively in clinically
suspected MS.36
Besides visualizing lesions in the brain,MR imagingmay be
used to image lesions associated with optic neuritis, neuromy-
elitis optica, and spinal cord MS. Optic neuritis is present in
50% of patients with MS and is frequently the presenting
sign. Gadolinium enhancement is a sensitive method for visu-
alizing optic neuritis and has a role, along with brain MR im-
aging and symptoms, in establishing a definitive diagnosis.37
The spinal cord is also frequently involved in MS and, for
most patients, both spinal cord and the brain are affected.38 In
25% of patients, however, lesions are present in the spinal
cord alone.33 Most spinal lesions are localized to the cervical
rather than the thoracic cord and tend to be multifocal and
asymmetric.39 At MR imaging, spinal lesions show increased
T2 signal intensity and, frequently, gadolinium enhancement.
In general, findings at spinal MR imaging are less definitive
compared with brain MR imaging for diagnosing MS.
Indications and protocols for suspected spinalMR imaging
remain an area of debate. Recommendations at the expert
meeting for use of MR imaging in patients with and without a
spinal presentation are summarized in Recommendation 4.
Consensus Statement. MR imaging is the optimal radio-
logic technique for supporting a diagnosis of MS in the brain
and spinal cord. Full exchange of imaging and clinical infor-
mation between radiologists and neurologists is essential for
reaching a correct diagnosis.
Role of Contrast Enhancement
The meeting participants noted a lack of expert guidance on
the role of contrast agents in MS and included extensive dis-
cussion on this topic. Estimates suggest that 35% of MR
imaging examinations are performed with contrast agents,
usually gadolinium-containing agents. Contrast enhancement
in MS increases the reliability of MR imaging to depict active
lesions34 and has a pivotal role in demonstrating dissemina-
tion in time, as defined in the revised McDonald criteria.2
Contrast enhancement also assists in excluding confounding
diagnoses, including other inflammatory conditions and tu-
mors. For these reasons, gadolinium enhancement is widely
recommended for the diagnosis and initial evaluation of MS.6
At some centers, contrast-enhanced MR imaging is addition-
ally performed to monitor the effects of therapy.
Consensus Statement.Contrast enhancement by using ga-
dolinium-containing agents increases the efficacy of MR im-
aging of MS lesions.
Characteristics of Contrast Agents
Anumber of gadolinium-containing contrast agents are avail-
able for use in MR imaging, including gadobenate dimeglu-
mine (MultiHance; Bracco, Milan, Italy), gadobutrol (Ga-
dovist; Bayer Schering Pharma, Berlin-Wedding, Germany),
gadodiamide (Omniscan; Nycomed Amersham, Oslo, Nor-
way), gadofosveset trisodium (Vasovist; EPIX Pharmaceuti-
cals, Lexington, Massachusetts), gadopentetate dimeglumine
(Magnevist; Schering, Berlin, Germany), gadoterate meglu-
mine (Dotarem; Guerbet, Aulnay-sous-Bois, France), gadot-
eridol (ProHance, Bracco), gadoversetamide (OptiMARK;
Mallinckrodt, St Louis, Missouri), and gadoxetic acid diso-
dium (Primovist, Bayer Schering Pharma). Most currently
available gadolinium-containing contrast agents are at a con-
centration of 0.5 mol/L, while gadobutrol is formulated at a
higher concentration of 1.0 mol/L.40
Stability. Gadolinium-containing contrast agents can be
classified by the molecular structure of their gadolinium-che-
late complex—whether macrocyclic or linear—and, within
the linear class, by whether they are ionic or nonionic.
Contrast agents with macrocyclic structures demonstrate
increased stability and a lower propensity to release gadolin-
ium ions compared with linear contrast agents.41 This was
confirmed in a recent study comparing the stability of contrast
agents in human serum under physiologic conditions.42 Re-
lease of gadolinium ions was substantially reduced for macro-
cyclic agents—gadobutrol, gadoteridol, and gadoterate
meglumine—relative to agents tested with linear structures
(Fig 3). The study also found that the addition of phosphate to
the serum at a concentration of 10 mmol/L (to simulate end-
stage renal disease) accelerated the release of gadolinium ions
from nonionic linear agents and, to a lesser degree, from ionic
linear agents, but that macrocyclic agents remained stable.
Release of gadolinium ions from contrast agents may be
relevant to the development of NSF. NSF is a rare outcome in
patients with severe kidney failure, characterized by thicken-
ing, induration, and hardening of the skin. Some workers at-
tribute NSF to gadolinium ions released from contrast
agents.43 In support of this still-debated association, clinical
Fig 3. Comparison of rates of Gd3 release for 1 mmol/L solutions of gadolinium-
containing contrast agents in native human serum from healthy volunteers at 37°C.
Reprinted with permission from Frenzel T, Lengsfeld P, Shirmer H, et al. Stability of
gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C.
Invest Radiol 2008;43:817–28.
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reports suggest that NSF is associated most commonly with
nonionic linear contrast agents and rarely with agents with
macrocyclic structures.44
ContrastDose andCharacteristics.Although there is con-
sensus on the benefits of gadolinium-based agents in MR im-
aging, debate continues over how best to use these agents to
optimize lesion visualization in MS.45
The standard dose of contrast agent for MR imaging of the
CNS is 0.1 mmol per kilogram of body weight, and this dose is
sufficient for diagnosis in most patients. Studies investigating
a range of pathologies, including brain tumors, gliomas, and
MS, indicate, however, that lesion detectionmay be improved
further with higher concentrations (0.2–0.3 mmol/kg).46-50
These higher concentrations may have a role in cases of diag-
nostic doubt following the standard 0.1 mmol/kg dose. As an
alternative to administering a contrast agent in sequential
doses, a dose-comparison study of gadobutrol in MS recom-
mended using a double dose (0.2 mmol/kg) at the initial as-
sessment, an approach that was endorsed by expert panel ex-
perience. A single injectionmay offer optimal balance in terms
of sensitivity, time, costs, and detection of active lesions.51
A physicochemical property of contrast agents relevant to
imaging performance is relaxivity, which defines the ability of
an agent to alter tissue relaxation rates. Complementing the-
oretic studies, higher relaxivity relates to increased imaging
performance in clinical trials comparing gadolinium-contain-
ing contrast agents.52-55 Gadobutrol has a higher relaxivity
than other macrocyclic agents currently available, leading to
the highest T1 shortening per volume.52,56
Acquisition Protocol by Using Contrast Agents. Another
consideration for optimizing lesion enhancement is the tim-
ing of image acquisition following contrast agent injection.45
A recent study reported that the sensitivity of MR imaging to
detect active MS lesions was progressively enhanced at up to
between 5 and 10 minutes postinjection of gadobutrol,47
which was supported by case study experience among expert
meeting participants (Fig 4). Although increasing enhance-
ment over time is an area for further investigation, themeeting
participants agreed that not all contrast agents share the char-
acteristic of gadobutrol of progressive enhancement
postinjection.
Consensus Statement. Complex stability is an important
safety consideration when selecting gadolinium-containing
contrast agents, especially in patients with renal disease. Phys-
icochemical characteristics (including concentration and re-
laxivity) and acquisition protocol influence imaging perfor-
mance. Gadobutrol meets the criterion of high complex
stability and provides the highest T1 shortening with high im-
age quality.
Acquisition Protocols for MR Imaging
Acquisition protocols for MR imaging in MS vary widely be-
tween centers, reflecting practitioner preference and local
availability of equipment. A comprehensive acquisition pro-
tocol may include a localizer scan, FLAIR sagittal, T2 and
FLAIR axial, pre- and postcontrast T1 axial, and (optionally)
DWI and 3D-T1-weighted spoiled gradient recalled-echo.
Simpler protocols offer time and cost savings relative to
Fig 4. Case study shows brain lesion enhancement with gadobutrol. Images were obtained at 3, 6, 9, and 12 minutes postinjection.
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more comprehensive protocols, can be standardized across
centers, and are likely to diagnose 90% of MS cases. A sim-
ple protocol was recommended by expert meeting
participants:
● Dual-echo and FLAIR, axial whole brain (to detect gray
matter lesions)
● Optional dual-echo or FLAIR, sagittal midline (to detect
corpus callosum lesions)
● Skip unenhanced T1 (provides little additional
information)
● Contrast-enhanced T1 scan
● Optional DWI (to differentiate other diagnoses).
A standard dose of contrast agent (0.1 mmol/kg) should be
injected before the first MR image. A scanner with at least 1T
optimizes image quality and tissue contrast.
Consensus Statement. A simple acquisition protocol that
can be standardized across centers offers advantages for diag-
nosing MS. A gadolinium-based contrast agent is recom-
mended for all diagnostic procedures.
Novel MR Imaging Techniques
Conventional MR imaging is associated with shortcomings
including low sensitivity to gray matter lesions and diffuse
whitematter involvement and a low capacity to predict clinical
status.3 Newer uses of existing MR imaging techniques, the
availability of novel contrast agents (eg, highmolar agents and
smart nanoparticles), and emerging techniques (eg, MR spec-
troscopy, DWI, DTI, perfusion-weighted imaging, and per-
meability testing of the BBB) offer opportunities for improved
specificity and sensitivity in diagnosing and monitoring
MS.3,33
Consensus Statement. Novel MR imaging techniques are
continuously being developed and appraised for roles in the
management of MS. Outside expert centers, T2 and gadolini-
um-enhanced T1MR imaging remainmainstay approaches in
practice.
Summary of Expert Meeting Recommendations
From discussion during the expert meeting, the participants
summarized 5 key recommendations for MR imaging in MS.
Recommendation 1: Diagnosis Versus Monitoring
● Applications ofMR imaging inMS should distinguish diag-
nosis from monitoring.
● MR imaging, especially used with contrast agents, has an
important role in diagnosing MS, excluding alternative di-
agnoses, and characterizing dissemination in space and time
according to the revised McDonald criteria.
Recommendation 2: The Clinical–MR Imaging Paradox
● MR imaging is currently not reliable for predicting the clin-
ical evolution of MS.
● Clinical decisions should not be based solely on the presence
of lesions detected at MR imaging.
Recommendation 3: Importance of the McDonald Criteria
● Standardized protocols and reporting procedures should be
uniformly adopted on the basis of the revised McDonald
criteria.
● This message should be communicated widely to radiolo-
gists and neurologists at congresses and other educational
opportunities.
● The McDonald criteria need to be adapted for Asian
populations.
Recommendation 4: Brain-Versus-Spinal Cord MR
Imaging
● For nonspinal cord presentation, brainMR imaging should
be performed. MR imaging investigation may be stopped if
there are sufficient lesions to support dissemination in
space. If that is not the case, additional spinal MR imaging
may be diagnostically helpful.
● For spinal cord presentation, start investigations with spinal
cordMR imaging, mainly to exclude alternative conditions.
If MS remains suspected, perform brain MR imaging to
identify additional lesions.
Recommendation 5: A Simple Standardized Protocol
● A simple standardized MR imaging protocol should be im-
plemented across centers.
● Dual-echo and FLAIR axial whole brain, precontrast du-
al-echo or FLAIR sagittal midline (optional), and con-
trast-enhanced T1 scanning should be performed.
● A scanner with at least 1T should be used.
● Use specific landmarks to achieve consistent section po-
sitioning, especially for serial studies.
● A gadolinium-containing contrast agent should be used for
all diagnostic procedures.
● Inject a standard dose of contrast agent (0.1 mmol/kg)
before the first MR imaging.
● For some contrast agents, there is evidence of a progres-
sive increase in lesion-detection rate due to delayed
enhancement.
● Consider high signal intensity and safety as well as com-
plex stability when selecting the contrast agent.
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